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Available online 28 September 2016Immunotherapy is the revolution in cancer treatment of this last decade. Amongmultiple approaches able to har-
ness the power of the immune system against cancer, T cell based immunotherapies represent one of the most
successful examples. In particular, biotechnological engineering of protein structures, like the T cell receptor or
the immunoglobulins, allowed the generation of synthetic peptides like chimeric antigen receptors and bispeciﬁc
antibodies that are able to redirect non-tumor speciﬁc T cells to recognize and kill leukemic cells. The anti-CD19/
CD3 bispeciﬁc antibody blinatumomab and anti-CD19 chimeric antigen receptor T cells (CART19) have produced
deep responses in patients with relapsed and refractory B-cell acute leukemias. However, although the majority
of these patients responds to anti-CD19 immunotherapy, a subset of them still relapses. Interestingly, a novel
family of leukemia escape mechanisms has been described, all characterized by the apparent loss of CD19 on
the surface of leukemic blasts. This extraordinary ﬁnding demonstrates the potent selective pressure of
CART19/blinatumomab that drives extreme and speciﬁc escape strategies by leukemic blasts. Patients with
CD19-negative relapsed leukemia have very poor prognosis and novel approaches to treat and ideally prevent
antigen-loss are direly needed. In this reviewwe discuss the incidence, mechanisms and therapeutic approaches
for CD19-negative leukemia relapses occuring after CD19-directed T cell immunotherapies and present our fu-
ture perspective.
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Anovel era for cancer treatment has started: redirecting the immune
system to recognize cancer cells has led to unprecedented responses in
many tumor subtypes [1]. The biotechnological engineering of known
protein structures (e.g. T cell receptor or immunoglobulins) led to the
generation of synthetic peptides like chimeric antigen receptors and
bispeciﬁc antibodies that are able to redirect non-tumor speciﬁc T
cells to recognize and kill leukemic cells. In the setting of B cell leuke-
mias and lymphomas, anti-CD19 chimeric antigen receptor T cells
(CART19) and anti-CD19/CD3 bispeciﬁc antibody (blinatumomab) led
to unprecedented results in multiple clinical trials [2,3]. These results
led to the FDA-approval of blinatumomab in 2014 [4] and to thees., 8-196 C, 3400 Civic Center
ella).
. on behalf of Research Network of Cassignment of the status of "breakthrough therapy" for several
CART19 products in 2015.
Blinatumomab is a bispeciﬁc T cell engager (BiTE), that includes
two different single-chain variable fragments (scFv) derived from
monoclonal antibodies against CD19 and CD3ε. This small artiﬁcial
protein structure is able to engage patient's own T cells and bring
them in close proximity to cancer cells leading to potent activation
and anti-tumor response [5]. One of the key factors to ensure the
high efﬁciency of this peptide is the structural design where the
anti-CD19 scFv has a higher afﬁnity compared to the anti-CD3 so
that a T cell can recognize and kill multiple B cells that are bound
to BiTE molecules [6–8]. With blinatumomab T cells are temporarily
redirected against cancer cells and continuous infusion of this drug is
required to ensure activity [9]. The BiTE concept was originally de-
veloped in Germany about 15 years ago [6] and is now extensively
used in the clinic for B-cell acute lymphoblastic leukemia (B-ALL)
[7,10]. On the other hand, CART are patient's own T cells that are
reengineered ex vivo to express a chimeric antigen receptor (CAR)
that empowers them to recognize one antigen expressed on theomputational and Structural Biotechnology. This is an open access article under the CC BY
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genetically modiﬁed, expanded and then reinfused back to the
patient in order to reconstitute a permanent anti-tumor immune
system. The concept of CAR started in the late ‘80 when groups in
Israel and Japan [11,12] conceptualized the design of a synthetic
immune receptor generated by the fusion of a scFv from a monoclo-
nal antibody with the intracellular signaling domain of the T cell
receptor (TCR, speciﬁcally the CD3ζ chain). One of the reasons of
the success of CART19 is the use of 2nd generation CAR structures
that, together with the CD3ζ chain, also include a costimulatory
domain, i.e. CD28 or 4-1BB (as opposed to 1st generation CAR that
included only the CD3ζ signaling domain without costimulation
domain). This way both signal 1 (antigen recognition) plus
signal 2 (costimulation) are summarized in a single construct,
recapitulating full T cell activation [13]. These two potent anti-
CD19 immunotherapies enable a non-tumor speciﬁc T cell to
recognize antigens expressed on the surface of the tumor cell with
the afﬁnity of a monoclonal antibody and triggering T cell activation
like a TCR.
It took many years for these concepts to emerge as an effective and
successful clinical therapy, but in the last 5–7 years blinatumomab
and CART19 have proven their immense potential leading to deep
tumor response in patients with otherwise extremely poor prognosis
[14–17]. In an early clinic trial, blinatumomab led to the clearance of min-
imal residual disease (MRD) in 80% of adult B-ALL patients treated [18,19].
A conﬁrmatory study enrolled 116 adult B-ALL patients with MRD (~60%
were in ﬁrst morphologic complete remission, CR) and showed 78%
MRD response with improved relapse-free survival (RFS) and overall sur-
vival (OS) [20,21]. In the setting of adult relapsed or refractory (r/r) B-ALL
patients with overt disease (N5% blasts in the bone marrow, BM)
blinatumomab led to ~69% CR (and CR with partial hematological recov-
ery, CRi) with 88% beingMRD-negative. About half (13/25) of the patients
reaching CR/CRi received an allo-SCT [22]. In a conﬁrmatory phase II trial,
189 adult patients with r/r B-ALL were treated with blinatumomab: 43%
of patients reached CR/CRi. Median RFS and OS were 6.1 and
5.9 months respectively. Only 43/189 patients continued treatment be-
yond cycle 2 and, again, about half of CR patients received allo-SCT. Pa-
tients with higher tumor burden (N50% blasts in the BM) had the
worse outcome (29% vs. 73% CR rate) [10]. Other studies showed prom-
ising activity of blinatumomab in pediatric ALL [23] and in Philadelphia-
positive ALL [24]. Regarding CART19, multiple groups have shown that
this approach can induce complete responses in 60–90% of B-ALL pa-
tients in clinical trials, both in pediatrics and adults [14,15,25]. In a recent
update of the pediatric study of the Univ. of Pennsylvania CART19
(CTL019), out of 59 patients 55 (93%)were in CR at 1month.With ame-
dian follow-up of 12 months RFS and OS were 55% and 79% respectively
[26].
Despite the excellent clinical responses of r/r B-ALL patients to CD19-
directed T cell therapies, a signiﬁcant number of patients still relapses. In
the blinatumomab study, 8/12 patients who did not receive subsequent
transplantation relapsed, and 2/13 of the ones receiving allo-SCT relapsed
[22]. For CART19 of 93%CR1month after therapy only 55% of the patients
are disease-free at 1 year, indicating that about half of the patients re-
lapse. Of note, no relapses have been observed after 1 year [26]. Therefore
despite very high short-term response rates, a signiﬁcant proportion of
patients still relapses, especially in the blinatumomab cohorts where no
prolonged T cell memory is established. In this context, two main types
of relapses are recognized: i. CD19+ relapses—where the leukemia phe-
notype is the same as before treatment: typically these relapses are linked
to poor T cell function or early CART cell disappearance; ii. CD19-negative
relapses—where the disease recurswith apparent loss of CD19: these re-
lapses can occur despite a strong activity of CART19or blinatumomaband
represent a novel mechanism of tumor escape. In this review we will
focus on this second type of relapses, discussing the incidence, the
current prognosis, and possible management strategies for CD19-nega-
tive relapses.2. Tumor Escape after CD19-Targeted Therapies
Since targeted therapies have been introduced for the treatment of
cancer, novel speciﬁcmechanisms of tumor escape have been observed.
As an example, the use of tyrosine kinase inhibitors for chronic myeloid
leukemia can lead to mutations in the BCR-ABL protein (T315I),
which confer resistance to the drug [27]; in melanoma, the efﬁcacy of
BRAF inhibitor can be abolished by mutations in BRAF or other alterna-
tive pathways [28]. The apparent CD19-loss is a speciﬁc tumor
escape mechanism observed for the ﬁrst time in the setting of
potent CD19-directed immunotherapies. These ﬁndings indicate how
cancer is a heterogeneous disease and can evolve over time adapting
to the environment.
In the setting of blinatumomab, when 16 of 20 adult B-ALL patients
with MRD+ disease achieved CR, 6 relapses occurred (all after
completing drug treatment), of which 2 were CD19-negative and 4
were CD19+. Four clinical relapses (2 CD19+, 2 CD19-negative)
were observed in patients who did not undergo transplantation after
completion of blinatumomab treatment and 2 in patients receiving
transplantation (all CD19+) [19,18]. In a more recent study in active
adult r/r B-ALL in CR after blinatumomab 3/10 relapses were CD19-
negative [22,29]. A recent report in abstract form described the
occurrence of a CD19-negative B-ALL relapse in a 69-year old patient
treated with blinatumomab; the authors suggest the use of a different
ﬂow cytometry gating strategy that does not rely exclusively on CD19
for early detection of these antigen-loss relapses [30].
In the setting of CART19, in a study run at the Children's Hospital of
Philadelphia and at the Univ. of Pennsylvania, 59 pediatric patients with
r/r B-ALL were treated with 2nd generation, 4-1BB costimulated
CART19 cells. In this cohort of heavily pretreated patients 93% reached
CR with 88% MRD negativity. At a median follow-up of 1 year, 34 pa-
tients had ongoing CR with only 6 receiving subsequent therapy. Twen-
ty patients subsequently relapsed: 13with CD19-disease [14,31,26]. In a
study using CD28-costimulated CART19, two patients who achieved
MRD-negative CR and were judged ineligible for allo-SCT both relapsed
with CD19-negative leukemia at 3 and 5 months. On the contrary, ten
patients who underwent allo-SCT in a CAR-induced MRD-negative
state remained disease-free with no unexpected peritransplant toxic-
ities [32]. More recently, the Seattle group reported that 9 patients out
of 29 (31%) adult B-ALL patients relapsed, and 3 (33%) of them were
CD19-negative (1myeloid phenotype switch) [17]. The group atMemo-
rial Sloan Kettering Cancer Center reported the occurrence of CD19-
negative relapses in 14% of adult B-ALL patients treated with CART19
(CD28 costimulation). In this trial, CR rate was 87% with 81%MRD neg-
ativity [16,33]. Therefore CD19-negative relapses are observed in B-ALL
patients treated with different CART19 products, independently of the
construct (different costimulation domains) and expansion/clinical pro-
tocol. However, wemight speculate that long-term persistence of CAR T
cells and the absence of subsequent allo-SCT could increase the chances
of antigen-loss relapse. No clear risk factor for the development of
CD19-negative relapses has been recognized, however, in our experi-
ence the previous exposure to blinatumomab pre-CART19 could possi-
bly represent a risk factor.
3. Possible Mechanisms of Escape
Due to the novelty of CD19 loss as an escape mechanism, there are
only few studies that investigated this condition and its possible mech-
anism. A paper published by our group, led by Dr. Elena Sotillo at the
Children Hospital of Philadelphia, demonstrated that, at least in a subset
of CD19-negative leukemias emerging after CD19-directed therapy,
mutations affecting the CD19 gene and CD19 splicing variants lacking
the CAR-recognized epitope are strongly enriched compared to samples
before CART19 treatment. In particular, exon 2 of CD19 was frequently
spliced out, leading to the disappearance of the CD19 epitope that is rec-
ognized by the FMC63-based antigen-binding moiety of CART19. This
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protein is still present but it is truncated, lacking the epitope that is nec-
essary to trigger CART19 recognition for lysis and CD19 detection by
ﬂow cytometry [34].
A variant of the CD19-negative relapses is myeloid lineage
switch. This phenomenon has been observed in murine models
where mice bearing E2a:PBX1 leukemia and treated with murine
CART19 developed at long-term myeloid CD19-negative relapses
(as opposed to CD19-negative lymphoid relapse at short-term)
[35]. In humans, the Seattle group reported the occurrence of mye-
loid switch relapse after CART19 in 2 out of 7 patients with B-ALL
harboring rearrangement of the mixed lineage leukemia (MLL)
gene. The relapses were demonstrated to be clonally related to the
pre-treatment disease. Interestingly different mechanisms seem to
have led to the myeloid relapses: for the ﬁrst patient, retention of
the immunoglobulin (Ig) rearrangement was observed in relapsed
myeloid blasts suggesting reprogramming or de-differentiation of a
previously committed B lymphoid blast; for the second patient ab-
sence of the Ig rearrangement could indicate myeloid differentiation
of a non-committed precursor or, most likely, the selection of a
preexisting CD19-negative myeloid clone by CART19 treatment
[36]. Of note, a similar phenomenon was observed in a 3-month-
old B-ALL infant with MLL-AFF1 rearrangement that was treated
with blinatumomab and relapsed on day 15 after treatment initia-
tion with a monoblastic AML (with identical karyotype as pre-
blinatumomab) [37]. Lineage switch is a rare event in ALL and
CD19-speciﬁc selective pressure may lead to a different blast differ-
entiation program or to the selection of minor myeloid CD19-
negative leukemic subpopulations giving rise to overt myeloid re-
lapses; however, the exact mechanisms are still poorly understood.
Our group recently suggested that minor CD19-negative subpopula-
tions, already observed in our initial report in 2013 [38], can pre-
exist in the leukemia bulk and can be selected for under the strong
pressure of CART19. In this study, we analyzed 6 B-ALL samples
that carried various rearrangements identiﬁable by ﬂuorescent in
situ hybridization (FISH) and in all of them we could identify a
minor CD19-negative subset that harbored the same FISH proﬁle as
the bulk leukemia. Further studies to investigate the role of these
minor subpopulations in CART19-treated patients are ongoing [39].
Lastly, another study described a patient with chronic lymphocytic
leukemia (CLL) (in the BM) and Richter syndrome (in the lymph
nodes) who was treated with CART19 and achieved 50% nodal
response and 80% reduction of CLL in the BM. Approximately 6-
month after CART19 the patient relapsed with a clonally related
CD19-negative plasmablastic lymphoma (PBL) and a minor popula-
tion of residual CD19-negative CLL. Clonal relationship between the
pre-treatment CLL and both the subsequent CD19-negative PBL and
CLL was conﬁrmed by molecular analysis (immunoglobulin
rearrangements). This report indicates that not only early-
precursor B-ALL but also differentiated B-cell neoplasms (e.g. CLL/
Richter syndrome) can develop antigen-loss escape [40].
Therefore several possible mechanisms have been described to
explain CD19-loss escapes but many more will be likely deﬁned in the
next few years as more and more patients are being treated with
blinatumomab and CART19 in the clinic. Regardless of the mechanisms
of CD19-negative relapse, these patients have a very poor prognosis and
novel therapeutic strategies are urgently needed.
4. Strategies to Avoid Antigen-Loss Relapses
Antigen-loss relapses are an emerging limitation of potent CD19-
targeted immunotherapies and, as discussed, are caused by the use of
very active selection agents that can recognize only one antigen on
leukemia cells. Novel strategies to avoid antigen loss are being tested
and include allogeneic transplantation and the co-targeting of multiple
markers on leukemic cells.Allogeneic stem cell transplantation (allo-SCT) represents a
possible additional treatment that could potentially reduce the risk of
antigen-loss relapse after CR is obtained with CD19-directed immuno-
therapies. In allo-SCT, patient's own hematopoiesis is ablated via high-
dose chemotherapy or radiation and new hematopoietic stem and pro-
genitor cells from a compatible donor are reinfused with the goal of
regenerating normal hematopoiesis. Together with the anti-leukemia
effect of the conditioning regimen, a new immune system that can po-
tentially recognize and destroy residual leukemic cells is established.
Since the graft-anti-leukemia effect generated by allo-SCT is not speciﬁc
for CD19+ cells, this approach could reduce relapse independently
from CD19 expression. There is no randomized clinical trial that proves
this hypothesis but the early phase clinical trials of CART19 and
blinatumomab suggest that patients receiving allo-SCT after CD19-
immunotherapies seem to have a lower frequency of developing
CD19-negative relapses. However, patients could potentially develop
CD19-negative relapses after CART19 even when followed by allo-SCT
due to the persistence of CART19-selected CD19-negative leukemia
initiating-cells. Moreover, many patients treated with blinatumomab
or CART19 have already received allo-SCT or are not eligible for this
treatment. Lastly, the toxicity related to allo-SCT is still high and this ap-
proach should be carefully evaluated in these heavily pretreated
patients.
Another strategy to tackle CD19-negative relapses is to use agents
targeting other markers on leukemic cells. Possible targets expressed
in both normal B-cells and B-ALL blasts are CD22, CD123 and CD20.
There are currently 3 clinical trials including CART22 for B-ALL. At
the NCI 4/9 pediatric and young adult B-ALL patients (some relapsing
with CD19-negative disease after CART19) treated with CART22
reached MRD-negative CR [41–43] At the University of Pennsylvania/
Children's Hospital of Philadelphia two CART22 trials (NCT02588456;
NCT02650414) recently opened for adults and pediatric patients with
r/r B-ALL. Other agents like the anti-CD22 antibody conjugated to
calicheamicin (inotuzumab ozogamicin) could potentially target
CD19-negative relapse [44]. Another target that is expressed on CD19-
negative blasts relapsing after CART19 is the IL-3 receptor α, CD123.
Our group demonstrated that anti-CD123 CART (CART123) are able to
eradicate CD19-negative blasts in preclinical xenograft models [39].
However, even though CD22, CD123 and in a lesser degree CD20 are
expressed in B-ALL including CD19-negative relapses we might specu-
late that targeting a single-marker could lead inevitably to antigen-
loss escape as observed for CD19. Therefore targetingmore than one an-
tigen on cancer cells represent a reasonable strategy to successfully
avoid antigen-loss. This approach hasn't been tested clinically yet, but
several pre-clinical studies have been published using both CART and
bi- or tri- speciﬁc antibodies, as depicted in Fig. 1. The Baylor College
of Medicine demonstrated that CART cells expressing both anti-HER2
CAR and anti-IL-13Rα2 zetakine (bi-CAR or dual CAR) can offset antigen
escape in glioblastoma pre-clinical models. Moreover, in their model,
biCART are also more active than the pooled combination of single-
expressing anti-HER2 and anti-IL13Rα2 CAR T cells [45]. In a recent
follow-up study they showed that a structural change to the biCAR
where the two antigen-recognizing domains are put in series on top
of the CAR backbone (Tandem CAR or tanCAR [46]) leads to better
anti-tumor activity as compared to biCART [47]. In another report
from the same group, pooled co-targeting of MUC1 and PSCA with
CART in prostate cancer preclinical models led to reduced antigen es-
capes [48]. All these studies evaluated antigen-loss in preclinicalmodels
of solid tumors, however in clinical trials CART have not demonstrated
to lead to overt antigen loss in solid tumors probably because of their
limited activity recorded so far. Preliminary clinical data in
glioblastoma patients treated with anti-EGFRvIII CART seem to suggest
that residual tumor after therapy has lower expression of EGFRvIII
[49]. Our group recently demonstrated that co-targeting CD19 and
CD123 can treat and also prevent antigen loss in a clinically-relevant
preclinical model of CD19-negative leukemia escape. We used
Fig. 1. Different strategies to target 2 antigens on the surface of leukemic cells to avoid antigen-loss relapses. A. Chimeric antigen receptor T cells. Pooled CART are a 1:1 mixture of single–
speciﬁcity CART: each cell remains able to recognize only one target (e.g. CD19 or CD123). Dual (or bi-) CART: every T cell bears 2 distinct CAR structures able to recognize 2 different
targets (e.g. CD19 and CD123). Tandem CART: every T cell bears 1 CAR structure where 2 scFvs are built in series and are able to recognize 2 different targets (e.g. HER2 and IL13Rα2).
B. Trispeciﬁc antibodies. Trispeciﬁc antibodies carry 3 scFvs, two recognize tumor targets (e.g. CD123 and CD33) and one engages the immune system (e.g. CD16). Trispeciﬁc antibody
conjugates include 3 scFvs plus the respective Fabs; two recognize tumor targets (e.g. EGFR and HER2) and one engages the immune system (e.g.CD64). C. Bispeciﬁc antibody-toxin
conjugates. Bispeciﬁc antibody-toxin conjugates carry 2 scFvs that recognize tumor targets (e.g. CD19 and CD22) linked to a toxin (e.g. Diphtheria toxin).
360 M. Ruella, M.V. Maus / Computational and Structural Biotechnology Journal 14 (2016) 357–362leukemic blasts derived from a B-ALL patient before treatment with
CART19 when the disease was CD19 + CD123+ and after CART19
when the patient relapsed with CD19- CD123+ leukemia. Using a
modelwhere immunodeﬁcientmicewere engrafted with a 1:1mixture
of the leukemic cells from this patient before and after CART19 treat-
ment, we demonstrated that co-targetingwith CART19/123 can prevent
antigen-escape. We also demonstarted that, in primary B-ALL
xenografts, dual CART are more potent than pooled CART [39]. Other
important targets that are being evaluated for cotargeting strategies to
prevent antigen-escape are CD22 [50] and CD20 [51]. In antibody ther-
apeutics, targeting multiple antigens with tri-speciﬁc antibodies (2
tumor targets +/− an immune system-engaging domain like CD64) is
under investigation for solid tumors (targeting HER proteins, EGFR
and others) [52,53]. Trispeciﬁc (CD123, CD33, CD16) antibodies capable
of redirecting NK cells (through CD16) to kill leukemia have also been
developed [54]. A single-chain triple-body with speciﬁcity for CD19
and CD33 was shown to mediate effective lysis of mixed lineage leuke-
mia cells by dual-targeting and engagement of NK cells (via CD16) [55].
Anti CD22/CD19 immunotoxins are being evaluated in the clinic
(NCT00450944, NCT00889408, NCT02370160) and in the future could
be important modalities to prevent antigen-loss relapses [56,57]. Lastly,
mixed therapeutic combinations of CART19 (or blinatumomab)
plus other anti-leukemia antibodies or antibody-drug conjugates
(ADC) (such as the anti-CD20 rituximab or anti-CD22 inotuzumab
ozogamicin) could be evaluated to avoid CD19-negative escape.
5. Summary and Outlook
CART and blinatumomab immunotherapies are leading to high
response rates and complete remissions in relapsed and refractory
B-cell leukemia patients who otherwise carry very poor prognosis.
Unfortunately, a signiﬁcant subset of patients still relapses and most of
the relapses (especially for CART19 therapy) are characterized by the
apparent loss of CD19. Themechanism of this escape is still under inves-
tigation, while some reports suggest that convergence of acquiredmutations and alternative splicing of CD19 enables leukemic cells to re-
sist CART19 immunotherapy. Other mechanisms like the selection of
minor CD19-negative clones or the induction of a myeloid switch have
been described. It is likely that additional mechanismswill be described
in the near future as more patients are treated with these potent anti-
CD19 immunotherapies. Interestingly, to our knowledge, the vast ma-
jority of CD19-negative relapses have been recorded in the setting of
B-ALL and only one case has been reported in NHL (CLL). This phenom-
enon can be related to the fact thatmore B-ALL patients are treatedwith
CART19/blinatumomab as compared to NHL, but also it can reﬂect the
different biology of undifferentiated blasts (B-ALL) versus mature B
cells (NHL).
As we have learned with chemotherapy, the leukemia treatment
requires multiple agents used together to avoid relapse [58]. The
same concept may hold true for targeted immunotherapies as well
as for small molecule inhibitors. The use of single agents can lead
to speciﬁc escape mechanisms and it is likely that the use of com-
bined approaches will reduce these events. For CART19 and
blinatumomab the treatment of CD19-negative relapses is nowman-
aged with additional chemotherapy (with generally poor results),
anti-CD22 agents like inotuzumab ozogamicin, anti-CD22 CART or
other clinical trials; in these cases, the goal is to achieve remission
and, if possible, proceed to an allo-SCT. Novel approaches will in-
clude upfront treatment with dual-targeting agents, taking advan-
tage of markers that are commonly expressed in B-ALL like CD22,
CD123 and CD20. However, as we have learned with chemotherapy,
if the mechanism of resistance is linked to tumor adaptation, even
targeting 2 antigens may not be enough to achieve cure in all pa-
tients with all cancers. Speciﬁc cocktails of CART or antibodies able
to target speciﬁc antigens tailored for each patient could further en-
hance the efﬁcacy and frequency of durable cancer remissions. The
clinical experience with pediatric leukemias and testicular neoplasm
demonstrates the power of combinational approaches to treat cancer
and we believe that similar success will be reached with combined
immunotherapies.
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